Trusted Resources: People & Places
Online groups, photo galleries and blogs
Mount Sinai – Lysosomal Storage Disease ProgramLysosomal Storage Disease Program
Division of Medical Genetics
1428 Madison Ave (Cross street 99th)
New York, New York, United States
Email Phone Web
The Mount Sinai Hospital’s Lysosomal Storage Disease Program is dedicated to the management, treatment, and counseling for pediatric and adult patients with known lysosomal storage diseases (LSDs). Mount Sinai Hospital has been an international leader in the management and treatment of these rare disorders and has been a referral center for patients from all over the world.
Comprised of board certified specialists including medical geneticists, genetic counselors, nurse practitioners, a specialized infusion nurse, a social worker, and clinical and research coordinators, our center has long standing programs in Gaucher, Fabry and Niemann Pick Types A and B disease. It also has expanded to manage patients with Pompe disease, Lysosomal Acid Lipase Deficiency (LALD), Batten disease, and the Mucopolysaccharidoses (MPS).
We have a dedicated Infusion Center where patients with Gaucher, Fabry, Pompe, LALD, Batten disease, and Mucopolysaccharidoses (MPS) can receive regular treatment with enzyme replacement therapy. The Mucopolysaccharidoses (MPS) are a group of inherited metabolic disorders caused by missing or absent enzymes that function to break down molecules called glycosaminoglycans.
There is FDA-approved treatment for several forms of MPS. ERT is available for four forms of the disease – Aldurazyme (MPS I), Elaprase (MPS II), Vimizim (MPS IVA), Naglazyme (MPS VI), and Mepsevii (MPS VII). HSCT (stem cell transplant) is also considered a beneficial therapy for three forms of MPS – severe MPS I (Hurler syndrome), MPS VI (Maroteaux-Lamy syndrome), and MPS VII (Sly syndrome).
A Guide to Understanding MPS II (Hunter Syndrome)MPS II belongs to a group of inherited m...
Medical Travel Assistance Program (MTAP)Program provides financial assistance of...
Understanding Mucopolysaccharidosis Type VII (MPS VII) or Sly SyndromeMPS VII, also called Sly syndrome, is a ...
Features and Behavior of Valvular Abnormalities in Adolescent and Adult Patients in Mucopolysaccharidosis: An Echoca...Mucopolysaccharidoses, a rare inherited ...
Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th ...REGENXBIO Inc. (Nasdaq: RGNX) today anno...
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration With JCR PharmaceuticalsTakeda Pharmaceutical Company Limited an...
A Guide to Understanding MPS III (Sanfilippo Syndrome)MPS III belongs to a group of inherited ...